☰
✕
Home/ Pharmaceutical/ Global Dengue Treatment Market
Request for TOC Request for Sample
BUY NOW

Global Dengue Treatment Market Size, Share, and Trends Analysis Report – Industry Overview and Forecast to 2032

Pharmaceutical | Published Report | Jun 2024 | Global | 350 Pages | No of Tables: 649 | No of Figures: 57
Buy Now Request for Sample
Nucleus

Circumvent the Tariff challenges with an agile supply chain Consulting

Supply Chain Ecosystem Analysis now part of DBMR Reports

Global Dengue Treatment Market

Market Size in USD Billion

CAGR :  %

USD 980.45 Million USD 2,359.06 Million 2024 2032
Forecast Period
 2025 –2032
Market Size(Base Year)
USD 980.45 Million
Market Size (Forecast Year)
 USD 2,359.06 Million
CAGR
 %
Major Markets Players
  • Pfizer Inc.
  • Perrigo Company plc
  • GSK plc Dr. Reddy&rsquo
  • s Laboratories Ltd.
  • Fresenius Kabi USASun Pharmaceutical Industries Ltd.

Global Dengue Treatment Market Segmentation, By Strains (DENV-2, DENV-3, DENV-1, DENV-4, and Others), Type (Vaccines and Acetaminophen), Severity (Mild to Moderate Dengue and Severe Dengue), Route of Administration (Parenteral and Oral), Mode of Purchase (Prescription and Over-the-Counter (OTC)), Gender (Male and Female), Age (Adult, Pediatric, and Geriatric), End User (Hospital, Specialty Clinics, Home Healthcare, and Others), Distribution Channel (Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies) - Industry Trends and Forecast to 2032

Dengue Treatment Market

Dengue Treatment Market Size

  • The global dengue treatment market size was valued at USD 980.45 million in 2024 and is expected to reach USD 2,359.06 million by 2032, at a CAGR of 11.60% during the forecast period

  • The market growth is largely fueled by the rising incidence of dengue fever globally, particularly in endemic regions across Asia-Pacific, Latin America, and parts of Africa, leading to heightened demand for effective treatment options

  • Furthermore, increasing government initiatives, clinical research efforts, and advancements in antiviral and supportive therapies are driving innovation in treatment protocols. These converging factors are accelerating the development and adoption of dengue treatment solutions, thereby significantly boosting the industry's growth

Dengue Treatment Market Analysis

  •  Dengue treatment, encompassing supportive care and symptomatic relief for patients infected with the dengue virus, plays a crucial role in managing this mosquito-borne tropical disease, particularly in endemic regions where recurrent outbreaks strain public health systems

  • The rising incidence of dengue globally, fueled by climate change, urbanization, and inadequate vector control, is a primary driver of the dengue treatment market, with increasing government efforts and awareness campaigns also contributing to demand for rapid diagnostics, fluid therapy, and antiviral research

  • Asia Pacific dominated the dengue treatment market with the largest revenue share of 58.8% in 2024, characterized by high disease burden, large population base, and ongoing public health initiatives in countries such as India, Indonesia, and the Philippines, where outbreaks frequently result in increased healthcare resource utilization

  •  Latin America is expected to be the fastest growing region in the dengue treatment market during the forecast period due to improved disease surveillance systems, rising healthcare expenditure, and the development of new vaccine programs and hospital preparedness strategies

  • DENV-2 segment dominated the dengue treatment market with a market share of 35.1% in 2024, driven by its higher virulence and prevalence in severe dengue cases across Asia and Latin America

Report Scope and Dengue Treatment Market Segmentation 

Attributes

Dengue Treatment Key Market Insights

Segments Covered

  • By Strains: DENV-2, DENV-3, DENV-1, DENV-4, and Others

  • By Type: Vaccines and Acetaminophen

  • By Severity: Mild to Moderate Dengue and Severe Dengue

  • By Route of Administration: Parenteral and Oral

  • By Mode of Purchase: Prescription and Over-the-Counter (OTC)

  • By Gender: Male and Female

  • By Age: Adult, Pediatric, and Geriatric

  • By End User: Hospital, Specialty Clinics, Home Healthcare, and Others

  • By Distribution Channel: Retail Pharmacies, Hospital Pharmacies, and Online Pharmacies

Countries Covered

North America

  • U.S.

  • Canada

  • Mexico

Europe

  • Germany

  • France

  • U.K.

  • Netherlands

  • Switzerland

  • Belgium

  • Russia

  • Italy

  • Spain

  • Turkey

  • Rest of Europe

Asia-Pacific

  • China

  • Japan

  • India

  • South Korea

  • Singapore

  • Malaysia

  • Australia

  • Thailand

  • Indonesia

  • Philippines

  • Rest of Asia-Pacific

Middle East and Africa

  • Saudi Arabia

  • U.A.E.

  • South Africa

  • Egypt

  • Israel

  • Rest of Middle East and Africa

South America

  • Brazil

  • Argentina

  • Rest of South America

Key Market Players

  • Takeda Pharmaceutical Company Limited (Japan)

  • Sanofi. (France)

  • GSK plc (U. K.)

  • Merck & Co., Inc. (U.S.)

  • Johnson & Johnson Inc. (U.S.)

  • Abbott. U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Sun Pharmaceutical Industries Ltd. (India)

  • Cipla Ltd. (India)

  • Bharat Biotech International Ltd. (India)

  • Dr. Reddy's Laboratories Ltd. (India)

  • Zydus Lifesciences Ltd. (India)

  • Pfizer Inc. (U.S.)

  • Serum Institute of India Pvt. Ltd. (India)

  • InBios International, Inc. (U.S.)

  • GeneOne Life Science Inc. (South Korea)

  • Panacea Biotec Ltd. (India)

  • Bio Farma (Persero) (Indonesia)

  • Eubiologics Co., Ltd. (South Korea)

  • Sinovac Biotech Ltd. (China)

Market Opportunities

  • Rising Dengue Incidence in Emerging Economies

  • Development of Targeted Antiviral Therapies

Value Added Data Infosets

In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include in-depth expert analysis, pricing analysis, brand share analysis, consumer survey, demography analysis, supply chain analysis, value chain analysis, raw material/consumables overview, vendor selection criteria, PESTLE Analysis, Porter Analysis, and regulatory framework.

Dengue Treatment Market Trends

“Technological Advancements in Diagnostics and Vaccine Development”

  • A significant and accelerating trend in the global dengue treatment market is the rapid advancement in diagnostic technologies and next-generation vaccine development, aimed at improving early detection and prevention. These innovations are transforming the way dengue is managed, especially in high-burden regions

    • For instance, rapid diagnostic tests (RDTs) now offer faster and more accurate detection of dengue antigens and antibodies, enabling timely medical intervention. Products such as SD BIOLINE Dengue Duo and Abbott’s Panbio tests are being widely used in endemic areas due to their efficiency and ease of use

  • On the preventive front, vaccines such as QDENGA by Takeda are gaining regulatory approvals in several countries, offering protection against all four dengue virus serotypes without the need for prior infection. This marks a major improvement over earlier vaccines such as Dengvaxia, which had limitations based on serostatus

  • Integration of digital health platforms is supporting real-time dengue surveillance, allowing healthcare providers and authorities to track outbreaks, identify hotspots, and manage resources effectively. Mobile apps and AI-powered dashboards are increasingly used to predict trends and optimize patient response strategies

  • Pharmaceutical companies are also investing in research on antiviral therapies and immune modulators targeting specific stages of dengue infection. These therapies aim to reduce viral replication, inflammation, and complications, potentially leading to more targeted and effective treatment protocols in the future

  • The combination of smarter diagnostics, more effective vaccines, and evolving treatment options is driving a shift toward a more proactive and precise approach to dengue management. As public health agencies, biotech firms, and NGOs continue to collaborate, the global dengue treatment landscape is expected to become more resilient and responsive

  • The growing emphasis on innovation, early detection, and prevention is expected to drive substantial demand across hospitals, clinics, and public health programs, especially in countries with high dengue incidence, reshaping global treatment strategies in the coming years

Dengue Treatment Market Dynamics

Driver

“Rising Dengue Incidence and Public Health Awareness Fueling Demand”

  • The escalating global burden of dengue infections, particularly in tropical and subtropical regions, along with increasing public health awareness, is a major driver behind the growing demand for effective dengue treatment solutions

    • For instance, in July 2024, the World Health Organization (WHO) issued an alert regarding surging dengue cases across South Asia and Latin America, urging countries to scale up diagnostic, treatment, and prevention efforts. This has prompted governments and healthcare providers to expand access to testing kits, medications, and supportive care infrastructure

  • As awareness increases about the potential complications of severe dengue, especially among vulnerable populations such as children and the elderly, there is greater demand for accurate diagnostics, safe symptom-relief medications, and hospitalization support

  • Furthermore, the strengthening of public health systems and disease surveillance programs is driving early detection and timely treatment, leading to higher consumption of dengue-related pharmaceuticals and medical services

  • The emergence of newer vaccines and therapeutic candidates, combined with government-led immunization and outbreak management initiatives, is further reinforcing the market’s growth trajectory. The inclusion of dengue treatment in national healthcare strategies, coupled with international funding support, is ensuring wider access and bolstering overall market demand

Restraint/Challenge

“Limited Therapeutic Options and Regulatory Complexities”

  • The global dengue treatment market faces key challenges due to the lack of specific antiviral therapies and the regulatory hurdles surrounding vaccine approvals and drug development. Current treatment largely relies on symptomatic relief, which limits clinical effectiveness in managing severe cases

    • For instance, despite the availability of vaccines such as Dengvaxia and QDENGA, regulatory restrictions based on serostatus, age, or regional safety concerns have constrained widespread adoption. In some regions, previous safety controversies have also led to public skepticism and lower vaccine uptake

  • The absence of approved antivirals targeting dengue virus replication, coupled with the complexity of managing four distinct viral serotypes (DENV-1 to DENV-4), makes treatment development scientifically and commercially challenging. Drug candidates must demonstrate efficacy across all serotypes while maintaining a strong safety profile, especially in pediatric and immunocompromised populations

  • In addition, access to accurate diagnostics in low-resource settings remains inconsistent, potentially leading to misdiagnosis or delayed treatment. This hinders effective disease management and skews public health data used for policy-making

  • High development costs, long clinical trial timelines, and the need for large-scale safety evaluations further slow progress in new treatment options. Moreover, budgetary constraints in developing countries—where dengue is most prevalent—limit procurement and distribution of advanced therapies or vaccines

  • Overcoming these barriers will require increased R&D investment, streamlined regulatory pathways, and collaborative global health initiatives focused on scalable, safe, and cost-effective dengue treatment solutions

Dengue Treatment Market Scope

The market is segmented on the basis of strains, type, severity, route of administration, mode of purchase, gender, age, end user, and distribution channel

  • By Strains

On the basis of strains, the dengue treatment market is segmented into DENV-2, DENV-3, DENV-1, DENV-4, and Others. The DENV-2 segment dominated the market with the largest market revenue share of 35.1% in 2024, due to its widespread prevalence and association with more severe cases of dengue hemorrhagic fever and dengue shock syndrome. Health agencies and researchers prioritize DENV-2 in diagnostic and vaccine efforts because of its aggressive virulence profile and high outbreak frequency.

The DENV-3 segment is anticipated to witness the fastest growth rate from 2025 to 2032, driven by rising incidence in Southeast Asia and Latin America. The growing need for diagnostics and treatments targeting DENV-3 and its genetic diversity make it a key area of focus in ongoing research and vaccine development

  • By Type

On the basis of type, the market is segmented into vaccines and acetaminophen. The acetaminophen segment held the largest revenue share of 62.4% in 2024, as it remains the primary and WHO-recommended option for managing fever and pain in dengue patients due to its safety profile. Its broad availability as both prescription and OTC medicine, along with its affordability, makes it the first-line treatment across most geographies.

The vaccines segment is expected to grow rapidly over the forecast period due to the expanded approval and distribution of new vaccines such as QDENGA, which offer cross-serotype protection and are being integrated into national immunization schedules in multiple dengue-endemic countries.

  • By Severity

On the basis of severity, the market is segmented into mild to moderate dengue and severe dengue. The mild to moderate dengue segment accounted for the largest market share of 71.8% in 2024, as the majority of cases fall into this category and are managed with supportive care, including fluid therapy and fever reducers.

The Severe Dengue segment is projected to witness strong growth during forecast period, as health systems improve their capacity for early diagnosis and treatment of complications such as plasma leakage, bleeding, and organ impairment, especially in high-risk pediatric and geriatric populations.

  • By Route Of Administration

On the basis of route of administration, the market is segmented into parenteral and oral routes. The Oral segment dominated with a market share of 67.3% in 2024, owing to its widespread use in administering acetaminophen and other symptomatic treatments in outpatient and home settings.

The Parenteral segment is expected to grow steadily during forecast period, due to its critical role in hospital-based care for severe dengue, especially for IV fluids, electrolytes, and emerging injectable antivirals or monoclonal antibodies

  • By Mode Of Purchase

On the basis of mode of purchase, the market is segmented into prescription and over-the-counter (OTC). The OTC segment led with 58.1% market share in 2024, due to the wide availability of acetaminophen and other non-prescription medications that patients and caregivers use for mild to moderate symptom relief.

The Prescription segment is expected to grow during forecast period, with increased hospital admissions for severe cases and the integration of vaccines and investigational therapies into clinical practice under physician supervision

  • By Gender

On the basis of gender, the market is segmented into male and female. The male segment held a slightly higher market share of 51.6% in 2024, potentially due to higher outdoor exposure and occupational risk in vector-prone regions.

However, gender differences in treatment demand are minimal, and both segments are expected to grow in parallel with rising infection rates and healthcare access.

  • By Age

On the basis of age, the market is segmented into adult, pediatric, and geriatric. The pediatric segment led the market with a share of 42.5% in 2024, as children are particularly vulnerable to dengue and are prioritized in vaccination and supportive care programs.

The Geriatric segment is expected to grow fastest during forecast period, due to higher risk of severe complications and mortality, prompting more aggressive clinical management and hospital resource allocation for elderly patients.

  • By End User

On the basis of end user, the market is segmented into hospitals, specialty clinics, home healthcare, and others. Hospitals dominated the market with a revenue share of 44.9% in 2024, as they handle the bulk of moderate to severe cases requiring IV treatment, continuous monitoring, and emergency care.

Home Healthcare is anticipated to expand rapidly during forecast period, with the rising adoption of remote monitoring, at-home supportive care, and telemedicine for mild dengue cases.

  • By Distribution Channel

On the basis of distribution channel, the market is segmented into retail pharmacies, hospital pharmacies, and online pharmacies. Hospital Pharmacies held the highest share at 39.7% in 2024, driven by their central role in dispensing vaccines, IV fluids, and prescription medications for inpatients and emergency departments.

Online Pharmacies are expected to see the fastest growth during forecast period, due to increasing digital health adoption, particularly in urban centers where consumers prefer doorstep delivery for OTC dengue treatments and diagnostic kits.

Dengue Treatment Market Regional Analysis

  • Asia Pacific dominated the dengue treatment market with the largest revenue share of 58.8% in 2024, driven by high disease burden, large population base, and ongoing public health initiatives in countries such as India, Indonesia, and the Philippines, where outbreaks frequently result in increased healthcare resource utilization

  • The region's tropical climate and rapid urbanization contribute to year-round mosquito breeding and frequent outbreaks, prompting consistent demand for diagnostics, antipyretics, and hospital care

  • Widespread public health campaigns, expanding immunization programs, and growing awareness about dengue symptoms and complications have also played a key role in driving market growth

Brazil Dengue Treatment Market Insight

The Brazil leads the Latin American market due to its recurrent dengue outbreaks and proactive government interventions. National immunization programs and surveillance systems have been scaled up significantly. The introduction of dengue vaccines and the strengthening of vector control strategies are transforming Brazil into a focal point for regional market growth and public health innovation.

Mexico Dengue Treatment Market Insight

The Mexico’s dengue treatment market is experiencing robust growth, propelled by its endemic status and rising investment in healthcare infrastructure. Government-led vaccination initiatives, growing collaborations with pharmaceutical companies, and improvements in diagnostic accessibility are key growth factors. Mexico’s cross-border cooperation and focus on digital health tools are also reinforcing its efforts in disease control and treatment.

U.K. Dengue Treatment Market Insight

The U.K. dengue treatment market is anticipated to grow consistently during the forecast period due to rising travel-related infections and heightened awareness of tropical diseases. NHS initiatives and guidelines for early detection, particularly among travelers returning from endemic regions, have led to improved clinical outcomes. The availability of diagnostic services, coupled with the increasing role of private healthcare and travel clinics, supports the growing demand for dengue-related treatments and preventive care.

Germany Dengue Treatment Market Insight

The Germany dengue treatment market is expected to grow steadily, driven by increased surveillance of imported dengue cases and growing investment in diagnostic technologies. The country’s robust public health system and emphasis on preventive medicine have contributed to the rising use of point-of-care tests and vaccination among outbound travelers. With a growing awareness of climate-sensitive diseases, Germany is also seeing rising demand for travel advisory services and prophylactic care.

Asia-Pacific Dengue Treatment Market Insight

The Asia-Pacific dengue treatment market is projected to grow at the fastest CAGR during the forecast period of 2025 to 2032, owing to high endemicity, frequent outbreaks, and growing government initiatives across countries such as India, Indonesia, Thailand, and the Philippines. Increased investments in healthcare infrastructure, rising public awareness, and expanding vaccine access are key growth drivers. The presence of domestic manufacturers and international partnerships for R&D are improving affordability and availability of diagnostics, antipyretics, and hospital services across both urban and rural areas

Japan Dengue Treatment Market Insight

The Japan dengue treatment market is gaining momentum due to increased vigilance in outbreak management, especially after past domestic outbreaks. Public health authorities focus on rapid diagnostics, vector control, and travel advisory programs to minimize local transmission. The high-tech healthcare ecosystem in Japan supports early detection and effective symptomatic treatment, while ongoing clinical trials for antiviral candidates are further shaping the market outlook.

India Dengue Treatment Market Insight

The India dengue treatment market accounted for the largest revenue share in Asia Pacific in 2024, driven by high disease incidence, increasing healthcare expenditure, and strong public health campaigns. Government programs such as the National Vector Borne Disease Control Programme (NVBDCP) and expanding access to low-cost diagnostics and medications have accelerated early diagnosis and treatment. The country’s push toward smart healthcare infrastructure and public-private collaborations is significantly boosting the availability of dengue management resources across both public and private sectors.

Dengue Treatment Market Share

The dengue treatment industry is primarily led by well-established companies, including:

  • Takeda Pharmaceutical Company Limited (Japan)

  • Sanofi. (France)

  • GSK plc (U. K.)

  • Merck & Co., Inc. (U.S.)

  • Johnson & Johnson Inc. (U.S.)

  • Abbott U.S.)

  • F. Hoffmann-La Roche Ltd. (Switzerland)

  • Sun Pharmaceutical Industries Ltd. (India)

  • Cipla Ltd. (India)

  • Bharat Biotech International Ltd. (India)

  • Dr. Reddy's Laboratories Ltd. (India)

  • Zydus Lifesciences Ltd. (India)

  • Pfizer Inc. (U.S.)

  • Serum Institute of India Pvt. Ltd. (India)

  • InBios International, Inc. (U.S.)

  • GeneOne Life Science Inc. (South Korea)

  • Panacea Biotec Ltd. (India)

  • Bio Farma (Persero) (Indonesia)

  • Eubiologics Co., Ltd. (South Korea)

  • Sinovac Biotech Ltd. (China)

What are the Recent Developments in Global Dengue Treatment Market?

  • In April 2024, Takeda Pharmaceutical Company Limited announced the continued global rollout of its dengue vaccine, QDENGA, after receiving additional approvals in Latin American countries including Brazil and Colombia. The vaccine, designed to offer protection against all four dengue virus serotypes regardless of prior exposure, marks a major step forward in preventive care. This development underscores Takeda’s ongoing efforts to expand access to dengue prevention tools in high-burden regions and highlights growing regulatory acceptance of next-generation vaccines

  • In March 2024, the World Health Organization (WHO) issued updated dengue treatment and management guidelines, emphasizing early detection, fluid management, and community engagement. These guidelines are aimed at reducing the incidence of severe dengue cases and improving outcomes in low-resource settings. The revision reflects the WHO’s commitment to strengthening global health responses and improving treatment protocols in countries most affected by dengue

  • In February 2024, Abbott Laboratories introduced an upgraded version of its Panbio Dengue Rapid Diagnostic Test, which offers improved sensitivity and broader compatibility with field settings. This launch addresses the critical need for quick, accurate dengue detection, especially in rural or underserved regions. The innovation reflects the growing emphasis on decentralized testing and real-time outbreak response in dengue-endemic countries

  • In January 2024, Sanofi and the Pasteur Institute initiated a new phase II clinical trial for a monoclonal antibody therapy targeting dengue virus serotype 2. This therapeutic candidate is designed to neutralize the virus and reduce disease severity, offering hope for more targeted treatments beyond symptom relief. The trial represents an important step in diversifying the treatment pipeline and underscores the shift toward biologics in managing vector-borne diseases

  • In December 2023, India’s Ministry of Health and Family Welfare launched a nationwide “Dengue Free India” campaign focused on strengthening vector control, improving public awareness, and expanding hospital preparedness. The campaign includes distribution of diagnostic kits, availability of antipyretics at government clinics, and training of healthcare workers. This initiative illustrates the growing role of national health programs in combating dengue and highlights government commitment to reducing the disease burden through multi-faceted intervention strategies

SKU-

Get online access to the report on the World's First Market Intelligence Cloud

  • Interactive Data Analysis Dashboard
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
  • Harness the Power of Benchmark Analysis for Comprehensive Competitor Tracking

Table of Content

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW OF THE GLOBAL DENGUE TREATMENT MARKET

1.4 CURRENCY AND PRICING

1.5 LIMITATIONS

1.6 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 DBMR TRIPOD DATA VALIDATION MODEL

2.5 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.6 MULTIVARIATE MODELLING

2.7 MARKET APPLICATION COVERAGE GRID

2.8 PRODUCT LIFELINE CURVE

2.9 DBMR MARKET POSITION GRID

2.1 VENDOR SHARE ANALYSIS

2.11 SECONDARY SOURCES

2.12 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PESTEL ANALYSIS

4.2 PORTER’S FIVE FORCES

5 GLOBAL DENGUE TREATMENT MARKET: REGULATIONS

5.1 U.S. REGULATORY SCENARIO FOR DENGUE TREATMENT

5.2 EUROPE REGULATORY SCENARIO FOR DENGUE TREATMENT

5.3 DEVELOPING COUNTRIES REGULATORY FRAMEWORK

5.4 LEGISLATION FOR CONTROL OF DENGUE IN SINGAPORE

5.5 DVCRN DEVELOPING VACCINE REGULATORS NETWORK

 

6 MARKET OVERVIEW

6.1 DRIVERS

6.1.1 RISING DENGUE INCIDENCE RATE RESULT IN THE DEMAND FOR EFFECTIVE TREATMENT

6.1.2 RISING WAVE OF DENGUE VACCINE LAUNCHES

6.1.3 GOVERNMENT INITIATIVES AND VACCINATION PROGRAMS

6.1.4 GROWTH OF MEDICAL INSURANCE IN EMERGING COUNTRIES

6.2 RESTRAINTS

6.2.1 DELAY IN THE APPROVAL PROCESS OF VACCINES

6.2.2 LACK OF AWARENESS AND HEALTHCARE INFRASTRUCTURE FOR TREATMENT OF DENGUE

6.2.3 DIFFICULTY IN THE DETECTION ASSAY FOR DENGUE

6.3 OPPORTUNITIES

6.3.1 STRATEGIC COLLABORATION WITHIN THE PHARMACEUTICAL INDUSTRY FUELS THE MARKET

6.3.2 GROWING NUMBER OF PIPELINE VACCINES FOR DENGUE TREATMENT

6.3.3 RISING R&D INVESTMENT AND ACTIVITIES

6.4 CHALLENGES

6.4.1 HEALTHCARE SERVICES ARE LIMITEDLY ACCESSIBLE IN RURAL AREAS

6.4.2 HIGH COSTS OF TREATMENT RESTRICT THE FEASIBILITY OF COST-EFFECTIVE SOLUTIONS

7 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS

7.1 OVERVIEW

7.2 DENV-2

7.3 DENV-3

7.4 DENV-1

7.5 DENV-4

7.6 OTHERS

8 GLOBAL DENGUE TREATMENT MARKET, BY TYPE

8.1 OVERVIEW

8.2 VACCINES

8.2.1 DENGVAXIA (CYD-TDV)

8.2.2 QDENGA

8.3 ACETAMINOPHEN

8.3.1 PARENTERAL

8.3.2 ORAL

8.3.3 OTHER

 

9 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY

9.1 OVERVIEW

9.2 MILD TO MODERATE DENGUE

9.3 SEVERE DENGUE

10 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION

10.1 OVERVIEW

10.2 PARENTERAL

10.2.1 SUB-CUTANEOUS

10.2.2 INTRAVENOUS

10.3 ORAL

10.3.1 TABLET

10.3.2 CAPSULES

10.3.3 OTHERS

11 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE

11.1 OVERVIEW

11.2 PRESCRIPTION

11.3 OVER-THE-COUNTER (OTC)

12 GLOBAL DENGUE TREATMENT MARKET, BY GENDER

12.1 OVERVIEW

12.2 MALE

12.3 FEMALE

13 GLOBAL DENGUE TREATMENT MARKET, BY AGE

13.1 OVERVIEW

13.2 ADULT

13.3 PEDIATRIC

13.4 GERIATRIC

14 GLOBAL DENGUE TREATMENT MARKET, BY END USER

14.1 OVERVIEW

14.2 HOSPITAL

14.3 SPECIALTY CLINICS

14.4 HOME HEALTHCARE

14.5 OTHERS

15 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 RETAIL PHARMACIES

15.3 HOSPITAL PHARMACIES

15.4 ONLINE PHARMACIES

16 GLOBAL DENGUE TREATMENT MARKET, BY REGION

16.1 OVERVIEW

16.2 ASIA-PACIFIC

16.2.1 INDIA

16.2.2 CHINA

16.2.3 JAPAN

16.2.4 INDONESIA

16.2.5 MALAYSIA

16.2.6 THAILAND

16.2.7 AUSTRALIA

16.2.8 SOUTH KOREA

16.2.9 SINGAPORE

16.2.10 PHILIPPINES

16.2.11 REST OF ASIA-PACIFIC

16.3 SOUTH AMERICA

16.3.1 BRAZIL

16.3.2 ARGENTINA

16.3.3 REST OF SOUTH AMERICA

16.4 NORTH AMERICA

16.4.1 MEXICO

16.4.2 U.S.

16.4.3 CANADA

16.5 EUROPE

16.5.1 FRANCE

16.5.2 GERMANY

16.5.3 SPAIN

16.5.4 U.K.

16.5.5 BELGIUM

16.5.6 ITALY

16.5.7 NETHERLANDS

16.5.8 RUSSIA

16.5.9 SWITZERLAND

16.5.10 TURKEY

16.5.11 REST OF EUROPE

 

16.6 MIDDLE EAST AND AFRICA

16.6.1 EGYPT

16.6.2 SAUDI ARABIA

16.6.3 SOUTH AFRICA

16.6.4 U.A.E

16.6.5 ISRAEL

16.6.6 REST OF MIDDLE EAST AND AFRICA

17 GLOBAL DENGUE TREATMENT MARKET: COMPANY LANDSCAPE

17.1 COMPANY SHARE ANALYSIS: GLOBAL

17.2 COMPANY SHARE ANALYSIS: NORTH AMERICA

17.3 COMPANY SHARE ANALYSIS: EUROPE

17.4 COMPANY SHARE ANALYSIS: ASIA-PACIFIC

17.5 COMPANY SHARE ANALYSIS: SOUTH AMERICA

18 SWOT ANALYSIS

19 COMPANY PROFILE

19.1 SANOFI

19.1.1 COMPANY SNAPSHOT

19.1.2 REVENUE ANALYSIS

19.1.3 COMPANY SHARE ANALYSIS

19.1.4 PRODUCT PORTFOLIO

19.1.5 RECENT DEVELOPMENTS

19.2 TAKEDA PHARMACEUTICAL COMPANY LIMITED

19.2.1 COMPANY SNAPSHOT

19.2.2 REVENUE ANALYSIS

19.2.3 COMPANY SHARE ANALYSIS

19.2.4 PRODUCT PORTFOLIO

19.2.5 RECENT DEVELOPMENTS

19.3 VIATRIS INC.

19.3.1 COMPANY SNAPSHOT

19.3.2 REVENUE ANALYSIS

19.3.3 COMPANY SHARE ANALYSIS

19.3.4 PRODUCT PORTFOLIO

19.3.5 RECENT DEVELOPMENTS

19.4 JOHNSON & JOHNSON SERVICES, INC.

19.4.1 COMPANY SNAPSHOT

19.4.2 REVENUE ANALYSIS

19.4.3 COMPANY SHARE ANALYSIS

19.4.4 PRODUCT PORTFOLIO

19.4.5 RECENT DEVELOPMENT

19.5 GSK PLC.

19.5.1 COMPANY SNAPSHOT

19.5.2 REVENUE ANALYSIS

19.5.3 COMPANY SHARE ANALYSIS

19.5.4 PRODUCT PORTFOLIO

19.5.5 RECENT DEVELOPMENTS

19.6 AUROBINDO PHARMA

19.6.1 COMPANY SNAPSHOT

19.6.2 REVENUE ANALYSIS

19.6.3 PRODUCT PORTFOLIO

19.7 BAXTER

19.7.1 COMPANY SNAPSHOT

19.7.2 REVENUE ANALYSIS

19.7.3 PRODUCT PORTFOLIO

19.8 FRESENIUS KABI USA

19.8.1 COMPANY SNAPSHOT

19.8.2 PRODUCT PORTFOLIO

19.8.3 RECENT DEVELOPMENTS

19.9 HIKMA PHARMACEUTICALS

19.9.1 COMPANY SNAPSHOT

19.9.2 REVENUE ANALYSIS

19.9.3 PRODUCT PORTFOLIO

19.9.4 RECENT DEVELOPMENT

19.1 PERRIGO COMPANY PLC

19.10.1 COMPANY SNAPSHOT

19.10.2 REVENUE ANALYSIS

19.10.3 PRODUCT PORTFOLIO

19.10.4 RECENT DEVELOPMENT

19.11 PFIZER INC.

19.11.1 COMPANY SNAPSHOT

19.11.2 REVENUE ANALYSIS

19.11.3 PRODUCT PORTFOLIO

19.11.4 RECENT DEVELOPMENTS

19.12 SUN PHARMACEUTICAL INDUSTRIES LTD

19.12.1 COMPANY SNAPSHOT

19.12.2 REVENUE ANALYSIS

19.12.3 PRODUCT PORTFOLIO

19.12.4 RECENT DEVELOPMENT

 

19.13 TEVA PHARMACEUTICALS USA, INC.

19.13.1 COMPANY SNAPSHOT

19.13.2 REVENUE ANALYSIS

19.13.3 PRODUCT PORTFOLIO

19.13.4 RECENT DEVELOPMENT

20 QUESTIONNAIRE

21 RELATED REPORTS

List of Table

TABLE 1 THREE PHASES FOR HEALTH PROTECTION OUTLINED BY THE EUROPEAN WORLD HEALTH ORGANIZATION

TABLE 2 IMPACT OF DELAY IN APPROVAL PROCESS

TABLE 3 GLOBAL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 4 GLOBAL DENV-2 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 5 GLOBAL DENV-3 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 6 GLOBAL DENV-1 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 7 GLOBAL DENV-4 IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 8 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 9 GLOBAL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 10 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 11 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 12 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 13 GLOBAL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 14 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 15 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 16 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 17 GLOBAL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 18 GLOBAL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 19 GLOBAL MILD TO MODERATE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 20 GLOBAL SEVERE DENGUE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 21 GLOBAL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 22 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 23 GLOBAL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 24 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 25 GLOBAL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 26 GLOBAL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 27 GLOBAL PRESCRIPTION IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 28 GLOBAL OVER-THE-COUNTER (OTC) IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 29 GLOBAL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 30 GLOBAL MALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 31 GLOBAL FEMALE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 32 GLOBAL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 33 GLOBAL ADULT IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 34 GLOBAL PEDIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 35 GLOBAL GERIATRIC IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 36 GLOBAL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 37 GLOBAL HOSPITAL IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 38 GLOBAL SPECIALITY CLINICS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 39 GLOBAL HOME HEALTHCARE IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 40 GLOBAL OTHERS IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 41 GLOBAL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 42 GLOBAL RETAIL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 43 GLOBAL HOSPITAL PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 44 GLOBAL ONLINE PHARMACIES IN DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 45 GLOBAL DENGUE TREATMENT MARKET, BY REGION, 2022-2031 (USD MILLION)

TABLE 46 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 47 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 48 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 49 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 50 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 51 ASIA-PACIFIC VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 52 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 53 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 54 ASIA-PACIFIC ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 55 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 56 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 57 ASIA-PACIFIC PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 58 ASIA-PACIFIC ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 59 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 60 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 61 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 62 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 63 ASIA-PACIFIC DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 64 INDIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 65 INDIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 66 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 67 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 68 INDIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 69 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 70 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 71 INDIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 72 INDIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 73 INDIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 74 INDIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 75 INDIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 76 INDIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 77 INDIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 78 INDIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 79 INDIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 80 INDIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 81 CHINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 82 CHINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 83 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 84 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 85 CHINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 86 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 87 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 88 CHINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 89 CHINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 90 CHINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 91 CHINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 92 CHINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 93 CHINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 94 CHINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 95 CHINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 96 CHINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 97 CHINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 98 JAPAN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 99 JAPAN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 100 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 101 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 102 JAPAN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 103 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 104 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 105 JAPAN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 106 JAPAN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 107 JAPAN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 108 JAPAN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 109 JAPAN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 110 JAPAN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 111 JAPAN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 112 JAPAN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 113 JAPAN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 114 JAPAN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 115 INDONESIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 116 INDONESIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 117 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 118 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 119 INDONESIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 120 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 121 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 122 INDONESIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 123 INDONESIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 124 INDONESIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 125 INDONESIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 126 INDONESIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 127 INDONESIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 128 INDONESIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 129 INDONESIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 130 INDONESIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 131 INDONESIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 132 MALAYSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 133 MALAYSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 134 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 135 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 136 MALAYSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 137 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 138 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 139 MALAYSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 140 MALAYSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 141 MALAYSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 142 MALAYSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 143 MALAYSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 144 MALAYSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 145 MALAYSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 146 MALAYSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 147 MALAYSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 148 MALAYSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 149 THAILAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 150 THAILAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 151 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 152 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 153 THAILAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 154 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 155 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 156 THAILAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 157 THAILAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 158 THAILAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 159 THAILAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 160 THAILAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 161 THAILAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 162 THAILAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 163 THAILAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 164 THAILAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 165 THAILAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 166 AUSTRALIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 167 AUSTRALIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 168 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 169 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 170 AUSTRALIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 171 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 172 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 173 AUSTRALIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 174 AUSTRALIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 175 AUSTRALIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 176 AUSTRALIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 177 AUSTRALIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 178 AUSTRALIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 179 AUSTRALIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 180 AUSTRALIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 181 AUSTRALIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 182 AUSTRALIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 183 SOUTH KOREA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 184 SOUTH KOREA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 185 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 186 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 187 SOUTH KOREA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 188 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 189 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 190 SOUTH KOREA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 191 SOUTH KOREA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 192 SOUTH KOREA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 193 SOUTH KOREA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 194 SOUTH KOREA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 195 SOUTH KOREA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 196 SOUTH KOREA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 197 SOUTH KOREA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 198 SOUTH KOREA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 199 SOUTH KOREA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 200 SINGAPORE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 201 SINGAPORE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 202 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 203 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 204 SINGAPORE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 205 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 206 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 207 SINGAPORE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 208 SINGAPORE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 209 SINGAPORE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 210 SINGAPORE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 211 SINGAPORE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 212 SINGAPORE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 213 SINGAPORE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 214 SINGAPORE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 215 SINGAPORE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 216 SINGAPORE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 217 PHILIPPINES DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 218 PHILIPPINES DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 219 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 220 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 221 PHILIPPINES VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 222 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 223 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 224 PHILIPPINES ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 225 PHILIPPINES DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 226 PHILIPPINES DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 227 PHILIPPINES PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 228 PHILIPPINES ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 229 PHILIPPINES DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 230 PHILIPPINES DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 231 PHILIPPINES DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 232 PHILIPPINES DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 233 PHILIPPINES DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 234 REST OF ASIA-PACIFIC DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 235 SOUTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 236 SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 237 SOUTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 238 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 239 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 240 SOUTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 241 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 242 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 243 SOUTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 244 SOUTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 245 SOUTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 246 SOUTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 247 SOUTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 248 SOUTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 249 SOUTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 250 SOUTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 251 SOUTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 252 SOUTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 253 BRAZIL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 254 BRAZIL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 255 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 256 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 257 BRAZIL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 258 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 259 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 260 BRAZIL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 261 BRAZIL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 262 BRAZIL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 263 BRAZIL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 264 BRAZIL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 265 BRAZIL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 266 BRAZIL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 267 BRAZIL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 268 BRAZIL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 269 BRAZIL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 270 ARGENTINA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 271 ARGENTINA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 272 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 273 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 274 ARGENTINA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 275 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 276 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 277 ARGENTINA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 278 ARGENTINA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 279 ARGENTINA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 280 ARGENTINA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 281 ARGENTINA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 282 ARGENTINA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 283 ARGENTINA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 284 ARGENTINA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 285 ARGENTINA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 286 ARGENTINA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 287 REST OF SOUTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 288 NORTH AMERICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 289 NORTH AMERICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 290 NORTH AMERICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 291 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 292 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 293 NORTH AMERICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 294 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 295 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 296 NORTH AMERICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 297 NORTH AMERICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 298 NORTH AMERICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 299 NORTH AMERICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 300 NORTH AMERICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 301 NORTH AMERICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 302 NORTH AMERICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 303 NORTH AMERICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 304 NORTH AMERICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 305 NORTH AMERICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 306 MEXICO DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 307 MEXICO DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 308 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 309 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 310 MEXICO VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 311 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 312 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 313 MEXICO ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 314 MEXICO DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 315 MEXICO DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 316 MEXICO PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 317 MEXICO ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 318 MEXICO DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 319 MEXICO DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 320 MEXICO DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 321 MEXICO DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 322 MEXICO DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 323 U.S. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 324 U.S. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 325 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 326 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 327 U.S. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 328 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 329 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 330 U.S. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 331 U.S. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 332 U.S. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 333 U.S. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 334 U.S. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 335 U.S. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 336 U.S. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 337 U.S. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 338 U.S. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 339 U.S. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 340 CANADA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 341 CANADA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 342 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 343 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 344 CANADA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 345 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 346 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 347 CANADA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 348 CANADA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 349 CANADA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 350 CANADA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 351 CANADA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 352 CANADA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 353 CANADA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 354 CANADA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 355 CANADA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 356 CANADA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 357 EUROPE DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 358 EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 359 EUROPE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 360 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 361 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 362 EUROPE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 363 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 364 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 365 EUROPE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 366 EUROPE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 367 EUROPE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 368 EUROPE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 369 EUROPE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 370 EUROPE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 371 EUROPE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 372 EUROPE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 373 EUROPE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 374 EUROPE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 375 FRANCE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 376 FRANCE DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 377 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 378 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 379 FRANCE VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 380 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 381 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 382 FRANCE ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 383 FRANCE DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 384 FRANCE DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 385 FRANCE PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 386 FRANCE ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 387 FRANCE DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 388 FRANCE DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 389 FRANCE DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 390 FRANCE DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 391 FRANCE DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 392 GERMANY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 393 GERMANY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 394 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 395 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 396 GERMANY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 397 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 398 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 399 GERMANY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 400 GERMANY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 401 GERMANY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 402 GERMANY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 403 GERMANY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 404 GERMANY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 405 GERMANY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 406 GERMANY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 407 GERMANY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 408 GERMANY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 409 SPAIN DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 410 SPAIN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 411 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 412 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 413 SPAIN VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 414 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 415 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 416 SPAIN ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 417 SPAIN DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 418 SPAIN DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 419 SPAIN PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 420 SPAIN ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 421 SPAIN DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 422 SPAIN DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 423 SPAIN DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 424 SPAIN DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 425 SPAIN DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 426 U.K. DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 427 U.K. DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 428 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 429 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 430 U.K. VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 431 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 432 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 433 U.K. ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 434 U.K. DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 435 U.K. DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 436 U.K. PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 437 U.K. ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 438 U.K. DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 439 U.K. DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 440 U.K. DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 441 U.K. DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 442 U.K. DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 443 BELGIUM DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 444 BELGIUM DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 445 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 446 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 447 BELGIUM VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 448 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 449 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 450 BELGIUM ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 451 BELGIUM DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 452 BELGIUM DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 453 BELGIUM PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 454 BELGIUM ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 455 BELGIUM DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 456 BELGIUM DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 457 BELGIUM DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 458 BELGIUM DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 459 BELGIUM DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 460 ITALY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 461 ITALY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 462 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 463 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 464 ITALY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 465 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 466 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 467 ITALY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 468 ITALY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 469 ITALY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 470 ITALY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 471 ITALY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 472 ITALY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 473 ITALY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 474 ITALY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 475 ITALY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 476 ITALY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 477 NETHERLANDS DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 478 NETHERLANDS DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 479 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 480 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 481 NETHERLANDS VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 482 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 483 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 484 NETHERLANDS ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 485 NETHERLANDS DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 486 NETHERLANDS DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 487 NETHERLANDS PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 488 NETHERLANDS ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 489 NETHERLANDS DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 490 NETHERLANDS DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 491 NETHERLANDS DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 492 NETHERLANDS DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 493 NETHERLANDS DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 494 RUSSIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 495 RUSSIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 496 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 497 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 498 RUSSIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 499 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 500 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 501 RUSSIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 502 RUSSIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 503 RUSSIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 504 RUSSIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 505 RUSSIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 506 RUSSIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 507 RUSSIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 508 RUSSIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 509 RUSSIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 510 RUSSIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 511 SWITZERLAND DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 512 SWITZERLAND DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 513 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 514 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 515 SWITZERLAND VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 516 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 517 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 518 SWITZERLAND ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 519 SWITZERLAND DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 520 SWITZERLAND DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 521 SWITZERLAND PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 522 SWITZERLAND ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 523 SWITZERLAND DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 524 SWITZERLAND DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 525 SWITZERLAND DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 526 SWITZERLAND DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 527 SWITZERLAND DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 528 TURKEY DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 529 TURKEY DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 530 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 531 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 532 TURKEY VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 533 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 534 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 535 TURKEY ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 536 TURKEY DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 537 TURKEY DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 538 TURKEY PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 539 TURKEY ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 540 TURKEY DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 541 TURKEY DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 542 TURKEY DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 543 TURKEY DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 544 TURKEY DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 545 REST OF EUROPE DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 546 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY COUNTRY, 2022-2031 (USD MILLION)

TABLE 547 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 548 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 549 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 550 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 551 MIDDLE EAST AND AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 552 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 553 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 554 MIDDLE EAST AND AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 555 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 556 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 557 MIDDLE EAST AND AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 558 MIDDLE EAST AND AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 559 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 560 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 561 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 562 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 563 MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 564 EGYPT DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 565 EGYPT DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 566 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 567 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 568 EGYPT VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 569 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 570 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 571 EGYPT ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 572 EGYPT DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 573 EGYPT DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 574 EGYPT PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 575 EGYPT ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 576 EGYPT DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 577 EGYPT DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 578 EGYPT DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 579 EGYPT DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 580 EGYPT DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 581 SAUDI ARABIA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 582 SAUDI ARABIA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 583 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 584 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 585 SAUDI ARABIA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 586 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 587 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 588 SAUDI ARABIA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 589 SAUDI ARABIA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 590 SAUDI ARABIA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 591 SAUDI ARABIA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 592 SAUDI ARABIA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 593 SAUDI ARABIA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 594 SAUDI ARABIA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 595 SAUDI ARABIA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 596 SAUDI ARABIA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 597 SAUDI ARABIA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 598 SOUTH AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 599 SOUTH AFRICA DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 600 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 601 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 602 SOUTH AFRICA VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 603 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 604 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 605 SOUTH AFRICA ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 606 SOUTH AFRICA DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 607 SOUTH AFRICA DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 608 SOUTH AFRICA PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 609 SOUTH AFRICA ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 610 SOUTH AFRICA DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 611 SOUTH AFRICA DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 612 SOUTH AFRICA DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 613 SOUTH AFRICA DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 614 SOUTH AFRICA DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 615 U.A.E DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 616 U.A.E DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 617 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 618 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 619 U.A.E VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 620 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 621 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 622 U.A.E ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 623 U.A.E DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 624 U.A.E DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 625 U.A.E PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 626 U.A.E ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 627 U.A.E DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 628 U.A.E DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 629 U.A.E DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 630 U.A.E DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 631 U.A.E DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 632 ISRAEL DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

TABLE 633 ISRAEL DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 634 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 635 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 636 ISRAEL VACCINES IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 637 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 638 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (VOLUME)

TABLE 639 ISRAEL ACETAMINOPHEN IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (ASP)

TABLE 640 ISRAEL DENGUE TREATMENT MARKET, BY SEVERITY, 2022-2031 (USD MILLION)

TABLE 641 ISRAEL DENGUE TREATMENT MARKET, BY ROUTE OF ADMINISTRATION, 2022-2031 (USD MILLION)

TABLE 642 ISRAEL PARENTERAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 643 ISRAEL ORAL IN DENGUE TREATMENT MARKET, BY TYPE, 2022-2031 (USD MILLION)

TABLE 644 ISRAEL DENGUE TREATMENT MARKET, BY MODE OF PURCHASE, 2022-2031 (USD MILLION)

TABLE 645 ISRAEL DENGUE TREATMENT MARKET, BY GENDER, 2022-2031 (USD MILLION)

TABLE 646 ISRAEL DENGUE TREATMENT MARKET, BY AGE, 2022-2031 (USD MILLION)

TABLE 647 ISRAEL DENGUE TREATMENT MARKET, BY END USER, 2022-2031 (USD MILLION)

TABLE 648 ISRAEL DENGUE TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2022-2031 (USD MILLION)

TABLE 649 REST OF MIDDLE EAST AND AFRICA DENGUE TREATMENT MARKET, BY STRAINS, 2022-2031 (USD MILLION)

List of Figure

FIGURE 1 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 2 GLOBAL DENGUE TREATMENT MARKET: DATA TRIANGULATION

FIGURE 3 GLOBAL DENGUE TREATMENT MARKET: DROC ANALYSIS

FIGURE 4 GLOBAL DENGUE TREATMENT MARKET: GLOBAL VS REGIONAL MARKET ANALYSIS

FIGURE 5 GLOBAL DENGUE TREATMENT MARKET: COMPANY RESEARCH ANALYSIS

FIGURE 6 GLOBAL DENGUE TREATMENT MARKET: INTERVIEW DEMOGRAPHICS

FIGURE 7 GLOBAL DENGUE TREATMENT MARKET: MARKET APPLICATION COVERAGE GRID

FIGURE 8 GLOBAL DENGUE TREATMENT MARKET: DBMR MARKET POSITION GRID

FIGURE 9 GLOBAL DENGUE TREATMENT MARKET: VENDOR SHARE ANALYSIS

FIGURE 10 GLOBAL DENGUE TREATMENT MARKET: SEGMENTATION

FIGURE 11 GROWING PHARMACEUTICAL INDUSTRY IS DRIVING THE GROWTH OF THE GLOBAL DENGUE TREATMENT MARKET FROM 2024 TO 2031

FIGURE 12 ON THE BASIS OF STRAINS, THE DENV-2 SEGMENT IS EXPECTED TO ACCOUNT FOR THE LARGEST SHARE OF THE GLOBAL DENGUE TREATMENT MARKET IN 2024 AND 2031

FIGURE 13 ASIA-PACIFIC IS EXPECTED TO DOMINATE THE GLOBAL DENGUE TREATMENT MARKET AND EXPECTED TO GROW WITH THE HIGHEST CAGR IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 14 ASIA-PACIFIC IS THE FASTEST-GROWING REGION FOR GLOBAL DENGUE TREATMENT MARKET IN THE FORECAST PERIOD OF 2024 TO 2031

FIGURE 15 DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF GLOBAL DENGUE TREATMENT MARKET

FIGURE 16 FINANCIAL BUDGET FOR VECTOR-BORNE -DISEASES INCLUDING DENGUE IN INDIA

FIGURE 17 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2023

FIGURE 18 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, 2024-2031 (USD MILLION)

FIGURE 19 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, CAGR (2024-2031)

FIGURE 20 GLOBAL DENGUE TREATMENT MARKET: BY STRAINS, LIFELINE CURVE

FIGURE 21 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2023

FIGURE 22 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, 2024-2031 (USD MILLION)

FIGURE 23 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, CAGR (2024-2031)

FIGURE 24 GLOBAL DENGUE TREATMENT MARKET: BY TYPE, LIFELINE CURVE

FIGURE 25 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2023

FIGURE 26 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, 2024-2031 (USD MILLION)

FIGURE 27 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, CAGR (2024-2031)

FIGURE 28 GLOBAL DENGUE TREATMENT MARKET: BY SEVERITY, LIFELINE CURVE

FIGURE 29 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2023

FIGURE 30 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, 2024-2031 (USD MILLION)

FIGURE 31 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, CAGR (2024-2031)

FIGURE 32 GLOBAL DENGUE TREATMENT MARKET: BY ROUTE OF ADMINISTRATION, LIFELINE CURVE

FIGURE 33 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2023

FIGURE 34 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, 2024-2031 (USD MILLION)

FIGURE 35 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, CAGR (2024-2031)

FIGURE 36 GLOBAL DENGUE TREATMENT MARKET: BY MODE OF PURCHASE, LIFELINE CURVE

FIGURE 37 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2023

FIGURE 38 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, 2024-2031 (USD MILLION)

FIGURE 39 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, CAGR (2024-2031)

FIGURE 40 GLOBAL DENGUE TREATMENT MARKET: BY GENDER, LIFELINE CURVE

FIGURE 41 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2023

FIGURE 42 GLOBAL DENGUE TREATMENT MARKET: BY AGE, 2024-2031 (USD MILLION)

FIGURE 43 GLOBAL DENGUE TREATMENT MARKET: BY AGE, CAGR (2024-2031)

FIGURE 44 GLOBAL DENGUE TREATMENT MARKET: BY AGE, LIFELINE CURVE

FIGURE 45 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2023

FIGURE 46 GLOBAL DENGUE TREATMENT MARKET: BY END USER, 2024-2031 (USD MILLION)

FIGURE 47 GLOBAL DENGUE TREATMENT MARKET: BY END USER, CAGR (2024-2031)

FIGURE 48 GLOBAL DENGUE TREATMENT MARKET: BY END USER, LIFELINE CURVE

FIGURE 49 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2023

FIGURE 50 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, 2024-2031 (USD MILLION)

FIGURE 51 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, CAGR (2024-2031)

FIGURE 52 GLOBAL DENGUE TREATMENT MARKET: BY DISTRIBUTION CHANNEL, LIFELINE CURVE

FIGURE 53 GLOBAL DENGUE TREATMENT MARKET: SNAPSHOT (2023)

FIGURE 54 GLOBAL DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 55 NORTH AMERICA DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 56 EUROPE DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

FIGURE 57 AISA-PACIFIC DENGUE TREATMENT MARKET: COMPANY SHARE 2022 (%)

Research Methodology

Data collection and base year analysis are done using data collection modules with large sample sizes. The stage includes obtaining market information or related data through various sources and strategies. It includes examining and planning all the data acquired from the past in advance. It likewise envelops the examination of information inconsistencies seen across different information sources. The market data is analysed and estimated using market statistical and coherent models. Also, market share analysis and key trend analysis are the major success factors in the market report. To know more, please request an analyst call or drop down your inquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market and primary (industry expert) validation. Data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Patent Analysis, Pricing Analysis, Company Market Share Analysis, Standards of Measurement, Global versus Regional and Vendor Share Analysis. To know more about the research methodology, drop in an inquiry to speak to our industry experts.

Customization Available

Data Bridge Market Research is a leader in advanced formative research. We take pride in servicing our existing and new customers with data and analysis that match and suits their goal. The report can be customized to include price trend analysis of target brands understanding the market for additional countries (ask for the list of countries), clinical trial results data, literature review, refurbished market and product base analysis. Market analysis of target competitors can be analyzed from technology-based analysis to market portfolio strategies. We can add as many competitors that you require data about in the format and data style you are looking for. Our team of analysts can also provide you data in crude raw excel files pivot tables (Fact book) or can assist you in creating presentations from the data sets available in the report.

Industry Related Reports

Browse Related Pages

Testimonial
Claudio Rondena Group Business Development & Strategic Marketing Director,
C.O.C Farmaceutici SRL
"This morning we were involved in the first part, the data presentation of MKT analysis, selected abstract from your work. The board team was really impressed and very appreciated, as well."
David Manning - Thermo Fisher Scientific Director, Global Strategic Accounts,
Dear Ricky, I want to thank you for the excellent market analysis (LIMS INSTALLED BASE DATA) that you and your team delivered, especially end of year on short notice. Sachin and Shraddha captured the requirements, determined their path forward and executed quickly.
You, Sachin and Shraddha have been a pleasure to work with – very responsive, professional and thorough. Your work is much appreciated.
Manager - Market Analytics, Uriah D. Avila - Zeus Polymer Solutions
Thank you for all the assistance and the level of detail in the market report. We are very pleased with the results and the customization. We would like to continue to do business.
Business Development Manager, (Pharmaceuticals Partner for Nasal Sprays) | Renaissance Lakewood LLC
DBMR was attentive and engaged while discussing the Global Nasal Spray Market. They understood what we were looking for and was able to provide some examples from the report as requested. DBMR Service team has been responsive as needed. Depending on what my colleagues were looking for, I will recommend your services and would be happy to stay connected in case we can utilize your research in the future.
Business Intelligence and Analytics, Ipsen Biopharm Limited

We are impressed by the CENTRAL PRECOCIOUS PUBERTY (CPP) TREATMENT report - so a BIG thanks to you colleagues.

Competition Analyst, Basler Web

I just wanted to share a quick note and let you know that you guys did a really good job. I’m glad I decided to work with you. I shall continue being associated with your company as long as we have market intelligence needs.

Marketing Director, Buhler Group

It was indeed a good experience, would definitely recommend and come back for future prospects.

COO, A global leader providing Drug Delivery Services

DBMR did an outstanding job on the Global Drug Delivery project, We were extremely impressed by the simple but comprehensive presentation of the study and the quality of work done. This report really helped us to access untapped opportunities across the globe.

Marketing Director, Philips Healthcare

The study was customized to our targets and needs with well-defined milestones. We were impressed by the in-depth customization and inclusion of not only major but also minor players across the globe. The DBMR Market position grid helped us to analyze the market in different dimension which was very helpful for the team to get into the minute details.

Product manager, Fujifilms

Thankful to the team for the amazing coordination, and helping me at the last moment with my presentation. It was indeed a comprehensive report that gave us revenue impacting solution enabling us to plan the right move.

Investor relations, GE Healthcare

Thank you for the report, and addressing our needs in such short time. DBMR has outdone themselves in this project with such short timeframe.

Market Analyst, Medincell

We found the results of this study compelling and will help our organization validate a market we are considering to enter. Thank you for a job well done.

Andrew - Senior Global Marketing Manager, Medtronic (US)

I want to thank you for your help with this report – It’s been very helpful in our business planning and it well organized.

Amarildo - Manager, Global Strategic Alignment MasterCard

We believe the work done by Data Bridge Team for our requirements in the North America Loyalty Management Market was fantastic and would love to continue working with your team moving forward.

Tor Hammer Green Nexus LLc

Thank you for your quick response to this unfortunate circumstance. Please extend my thanks to your reach team. I will be contacting you in the future with further projects

Tommaso Finocchiaro Market Intelligence Specialist Nippon Gasses

I acknowledge the difficulty given by the very short warning for this report, and I think that its quality and your delivering time have been very satisfying. Obviously, as a provider Data Bridge Market Research will be considered as a plus for future needs of Nippon Gases.

Yuki Kopyl (Asian Business Development Department) UENO FOOD TECHNO INDUSTRY, LTD. (JAPAN)

Xylose report was very useful for our team. Thank you very much & hope to work with you again in the future
Request for TOC Speak to Analyst Free Sample Report Inquire Before Buy Now
Request a Call
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Request for Demo
Please select country
Please enter Contact No.
Please enter job tital
Please enter company name
Office Number 402, Amanora
Chambers, Magarpatta Road, Hadapsar
Pune – 411028.

Reports

Market Insights

Support

Solutions

DMCA Protected © DataBridge - All Rights Reserved.

We Accept Payment